COMPARING THE CHARACTERISTICS OF COLORECTAL CANCER IN YOUNG VERSUS OLD PATIENTS
10.1136/gutjnl-2021-BSG.307

Introduction
The overall lifetime risk of developing colorectal cancer (CRC) is approximately 4% in men and women. Over the past few decades, there has been an increase in incidence of CRC in the young population (defined as 50 years and under) despite an opposite trend in the older population (over 50 years old). Furthermore, more advanced disease has been observed at the point of diagnosis in young patients. Although recognised environmental and genetic factors play a role in this increase, the exact aetiology in this age group is unknown, but is likely multifactorial. Our study aimed to compare the differences in presentations, tumour characteristics and outcomes in patients with CRC according to age group.

Methods
A prospectively maintained endoscopy database of all colorectal cancers at a London district general hospital between January 2019 and May 2021 was interrogated in conjunction with our colorectal multidisciplinary team meeting outcomes. Data were collected on age, presentation, indication for initial scope, tumour size and site, and biochemical parameters. We compared differences between the 55 year olds and under with the over 55 year olds. Categorical variables were analysed using the chi-squared test and the Fischer’s exact test. Continuous variable were analysed using two tailed T-test. Significant values were considered when p<0.05. All data was performed In R version 1.4.1106.

Results
There were 160 patients included in this study. There were 86 females and 74 males. The median age was 72 years old (IQR: 31-94). There were 39 patients in the 55 years and under category and 121 in the over 55 category. There were significant differences in initial presentation with younger patients most commonly presenting with rectal bleeding (33.3%) and abdominal pain (10.2%) whereas older patients presented with iron deficiency anaemia (28.1%) and change in bowel habits (19%) (p = <0.01). Furthermore, there was significantly more lymphovascular invasion in younger patients when compared with older patients (53.8% vs 33% p<0.03). In the younger population the sigmoid colon was the most common site of malignancy (25.6%) compared to the rectum in the older population (24.0%). There was no difference in TNM stage at presentation between the two groups (p=0.93). Figure 1 shows the survival analysis between the two groups.

Conclusions
Younger patients present differently than older patients with colorectal cancer. Older patients present much more commonly with iron deficiency anaemia compared with younger patients. Furthermore, younger patients present with greater lymphovascular invasion than older patients. Despite differences, survival appears to be similar between the two groups.

SIGMOIDOPEXY-ASSISTED PERCUTANEOUS ENDOSCOPIC COLOSTOMY (PEC) – A STEPWISE IMPROVEMENT IN SAFETY
John Frost*, Saud Ishaq, Elizabeth Gibson, Lauren Robinson, Neil Fisher. Russell’s Hall Hospital, Dudley, UK
10.1136/gutjnl-2021-BSG.308

Introduction
Percutaneous endoscopic colostomy (PEC) is an established alternative to surgery for recurrent sigmoid volvulus or pseudo-obstruction. Tube migration resulting in peritonitis remains a serious safety concern. Endoscopic sigmoidopexy allows fixation of the colon to the abdominal wall prior to PEC insertion, reducing the risk of tube migration or faecal leakage. We present our initial experience of sigmoidopexy-assisted PEC.

Methods
After endoscopic decompression of the colon, a suitable place for sigmoidopexy is identified (usually mid-sigmoid), using trans-illumination and/or finger indentation. A triangulated 3-point sigmoidopexy is then performed with a Pexact suturing device. A 15Fr Freka gastrostomy tube is then inserted within the sigmoidopexy points using a standard pull-through technique, to act as the PEC. A fatus bag is attached to the PEC and left on free drainage for 24 hours. Antibiotics are administered peri-procedurally. The sigmoidopexy sutures are removed after 14 days, and the PEC tube is left in situ for a minimum of 3 months.

Results
Over an 18 month period 12 patients had sigmoidopexy-assisted PEC (recurrent sigmoid volvulus 9, pseudo-obstruction 3) after MDT case selection. All cases were considered unsuitable for surgery after surgical review.

There were no procedural complications and no episodes of faecal peritonitis or other significant sepsis.
Of patients treated for volvulus (median follow up 10 months), 5 (55%) had PEC removal after 3 months without recurrence to date, whilst 2 (22%) had recurrent volvulus following PEC removal requiring further intervention (surgery 1, further PEC 1). One patient required regular venting from the PEC, hence tube not removed.

Two patients with pseudo-obstruction have ongoing venting via their PEC tube, whereas one patient removed their PEC 3 weeks post insertion. Despite forcible removal, there was no observed faecal peritonitis.

Conclusions Sigmoidopexy-assisted PEC appears to be a safe and effective technique, with no significant post-procedural complications in this case series. Two patients developed recurrent sigmoid volvulus after tube removal, suggesting a need to leave tubes in situ for longer than the 3 months used in our initial protocol.

**Abstracts**

**PTH-106**

**PATIENT PERCEPTION OF FIT IN THE DIAGNOSTIC PATHWAY FOR COLORECTAL CANCER: A MIXED METHOD STUDY**

1,2Theo Georgiou Delisle*, Nigel D’Souza, Bethan Davies, Sally Benten, Michelle Chen, Helen Ward, Muti Abulafi, Croydon University Hospital, London, UK; 3Imperial College London, UK; 4Royal Surrey County Hospital, Guildford, UK; 5RM Partners, The West London Cancer Alliance, UK

10.1136/gutjnl-2021-BSG.309

**Introduction** The faecal immunochemical test (FIT) is a non-invasive, quantitative immunoassay detecting haemoglobin in faeces. FIT is used in bowel cancer screening in the UK for the asymptomatic population. There is mounting evidence of the high diagnostic accuracy of FIT in patients with suspected colorectal cancer (CRC) symptoms. To date, there is no research on usability and perception of FIT in these patients. The aim of the study was to better understand variation in patient perception and acceptability of FIT for patients with suspected CRC symptoms.

**Methods** A questionnaire was co-developed with patients and included 21 statements covering four themes: FIT feasibility, faecal aversion, patient knowledge and future intentions. Questionnaires were sent to patients with suspected CRC symptoms participating in the NICE FIT study, a multicentre study determining FIT sensitivity for CRC in symptomatic patients. Logistic regression analysis explored differences in patients’ test perception by demographic factors. In addition, semi-structured interviews were conducted with patients who had experienced suspected CRC symptoms and used FIT.

**Results** 1151 questionnaires (31% response rate) were analysed; 90.1% of patients found faecal collection straightforward, (95% CI 88.3% - 91.8%), 76.3% disagreed FIT was unhygienic (95% CI 73.7% - 78.6%), 78.0% would prefer FIT to colonoscopy (95% CI 75.6% - 80.4%). Preference for FIT over colonoscopy increased with age (OR 1.02; 95% CI 1.01 - 1.03). Intention to use FIT again was stronger in patients who successfully used FIT than those who did not (OR 11.19; 95% CI 2.75 - 45.52) and people of white compared to other ethnicities (OR 3.17; 95% CI 1.31 - 7.68). 15 patient interviews were completed. Patient interviews identified that patients’ perception of GP workload could influence test return preferences with patients concerned that returning FIT directly to GPs could add to GP workload. Patients’ perception of missing CRC using FIT, and their personal perception of acceptable risk of missed cancer was variable with evidence that patients’ personal experience of cancer risk could influence future behaviour in investigation preference.

**Conclusions** While most patients found FIT practical and hygienic, perception differences were found. Developing strategies to engage patients with more negative FIT perception should be part of symptomatic FIT pathways. FIT recommendation from GPs should trigger a simple patient pathway with rapid secondary care input.

**PTH-107**

**MANDATORY USE OF FAECAL IMMUNOCHEMICAL TEST WILL IMPROVE TRIAGE FOR LOWER GI CANCER REFERRALS**

1Karen Russell*, 1Peter Coyne, 2Steph Needham, 3Katie Elliott, 4David Nylander. 5Newcastle Upon Tyne NHS Foundation Trust, Newcastle Upon Tyne, UK; 6Northern Cancer Alliance, Newcastle upon Tyne, UK

10.1136/gutjnl-2021-BSG.310

Prior to the coronavirus pandemic data from our hospital showed a 39% increase in referrals through lower GI (LGI) cancer pathway (CWT) from 2018 to 2019 with 30% having 1st contact in 14 days.

We structure endoscopy lists and outpatient clinics so that some appointment ‘slots’ are kept exclusively for LGI CWT. After restart of services post COVID ‘lockdown’ in April 2020 we attempted to send all patients referred via LGI CWT a FIT kit. We wanted to look at local data to assess the following:

a) Proportion of patients referred via LGI CWT with final cancer diagnosis i.e the conversion rate (c-rate).

b) Proportion with first hospital contact within 14 days.

c) Impact of triage using FIT ≥10 as standard for urgent investigation in the absence of alarm symptoms e.g. palpable abdo/rectal mass or weight loss on colorectal cancer (CRC) diagnosis – assessed by calculating negative predictive value (NPV) of a FIT≥10 for CRC in this cohort.

**Method** We prospectively collected the following from LGI CWT referrals from 1/4/20 to 31/12/20: Patient demographics, referral ‘symptom’, dates patients referred and first hospital contact (‘seen’), FIT result and final diagnosis of cancer.

**Results** 1591 patients were referred in the period. 1404 (88.2%) had a FIT result. 51 cancers diagnosed in this cohort (includes 1 patient with pancreatic and 1 with possible gallbladder cancer) i.e. a c-rate of 3.2% for all cancer (3.1% for CRC). All apart from one of the patients with a final diagnosis of CRC referred via CWT had FIT ≥10. So when considering those with a FIT result, c-rate was 7.8% for patients with FIT ≥10 and 0.1% for FIT<10.

Table 1 below shows the main presenting symptom with cancer proportion and FIT level

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Cancer Proportion</th>
<th>FIT ≥10</th>
<th>FIT &lt;10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal pain</td>
<td>55.1%</td>
<td>10</td>
<td>2</td>
</tr>
</tbody>
</table>

1 x metastatic pancreas cancer. Presented with abdominal pain and weight loss